Double contrast MRI could sharpen brain diagnosis
NCT ID NCT03270059
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using two contrast agents (gadolinium and ferumoxytol) in one MRI session can improve the detection and diagnosis of brain and central nervous system abnormalities. About 150 participants with neurological symptoms or known brain lesions will undergo imaging. The goal is to see if this combined approach provides clearer images of blood vessels and abnormal tissue, potentially leading to more accurate diagnoses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New program aims to make cancer surgery safer for seniors
- Brain zap study: will precision radiation save your memory?
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
- Radiation before brain surgery may stop cancer's return
- Brain tumor clues in spinal fluid: mayo clinic launches major biomarker hunt